Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells.

Washimi K, Yokose T, Yamashita M, Kageyama T, Suzuki K, Yoshihara M, Miyagi Y, Hayashi H, Tsuji S.

PLoS One. 2012;7(7):e39889. doi: 10.1371/journal.pone.0039889. Epub 2012 Jul 2.

2.

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.

Br J Cancer. 2010 Aug 10;103(4):517-23. doi: 10.1038/sj.bjc.6605786. Epub 2010 Jul 13.

3.

Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE).

Wali A, Morin PJ, Hough CD, Lonardo F, Seya T, Carbone M, Pass HI.

Lung Cancer. 2005 Apr;48(1):19-29. Epub 2004 Dec 18.

PMID:
15777968
4.

Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium.

Ito A, Hagiyama M, Mimura T, Matsumoto M, Wakayama T, Iseki S, Yokozaki H, Okada M.

Lab Invest. 2008 May;88(5):504-14. doi: 10.1038/labinvest.2008.15. Epub 2008 Mar 10.

5.

Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.

Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y.

Mod Pathol. 2007 Feb;20(2):215-20. Epub 2006 Dec 22.

6.

Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.

Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K.

Virchows Arch. 2013 Jan;462(1):83-93. doi: 10.1007/s00428-012-1344-6. Epub 2012 Nov 28.

PMID:
23187830
7.

Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.

Attanoos RL, Galateau-Salle F, Gibbs AR, Muller S, Ghandour F, Dojcinov SD.

Histopathology. 2002 Jul;41(1):42-9.

PMID:
12121236
8.

Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.

Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.

Cancer Invest. 2013 Jan;31(1):43-50. doi: 10.3109/07357907.2012.749265. Epub 2012 Dec 18.

PMID:
23249166
9.

The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.

Zimling ZG, Jørgensen A, Santoni-Rugiu E.

Histopathology. 2012 May;60(6B):E96-105. doi: 10.1111/j.1365-2559.2012.04196.x. Epub 2012 Mar 6.

PMID:
22394205
10.

Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.

Matsumoto S, Nabeshima K, Hamasaki M, Shibuta T, Umemura T.

Med Oncol. 2014 Dec;31(12):303. doi: 10.1007/s12032-014-0303-2. Epub 2014 Oct 31.

PMID:
25358615
11.

Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?

Mlika M, Ayadi-Kaddour A, Ksantini M, Bouraoui S, Mzabi S, El Mezni F.

J Immunoassay Immunochem. 2013;34(2):111-25. doi: 10.1080/15321819.2012.690356.

PMID:
23537297
12.

CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.

Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, Scagliotti G, Novello S, Orecchia S, Ruffini E, Rapa I, Righi L, Volante M, Funaro A.

Oncotarget. 2014 Aug 15;5(15):6191-205.

13.

Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.

Wagner D, Bourne PA, Yang Q, Goldman BI, Lewis JS Jr, Xu H.

Appl Immunohistochem Mol Morphol. 2008 May;16(3):301-7. doi: 10.1097/PAI.0b013e3181507893.

PMID:
18301236
15.

Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.

Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G.

Int J Oncol. 2010 Aug;37(2):437-44.

PMID:
20596671
16.

Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.

Chaouche-Mazouni S, Scherpereel A, Zaamoum R, Mihalache A, Amir ZC, Lebaïli N, Delaire B, Gosset P.

Ann Diagn Pathol. 2015 Aug;19(4):193-7. doi: 10.1016/j.anndiagpath.2015.03.007. Epub 2015 Apr 14.

PMID:
25935651
17.

A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.

Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D.

J Mol Diagn. 2010 Nov;12(6):771-9. doi: 10.2353/jmoldx.2010.090169. Epub 2010 Sep 23.

18.

c-Met expression and MET amplification in malignant pleural mesothelioma.

Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC.

Ann Diagn Pathol. 2016 Aug;23:1-7. doi: 10.1016/j.anndiagpath.2016.04.007. Epub 2016 Apr 30.

PMID:
27402216
19.

Osteopontin is not a specific marker in malignant pleural mesothelioma.

Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M.

Int J Biol Markers. 2009 Apr-Jun;24(2):112-7.

PMID:
19634115
20.

MicroRNAs dysregulation in human malignant pleural mesothelioma.

Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, Martini F, Tognon MG.

J Thorac Oncol. 2011 May;6(5):844-51. doi: 10.1097/JTO.0b013e31820db125.

Supplemental Content

Support Center